The evolving role of genomics in the treatment of WM: MYD88, CXCR4, and TP53
Steven Treon, MD, PhD, Dana-Farber Cancer Institute, Boston, MA, discusses the evolving role of genomics in the treatment of Waldenström's macroglobulinemia (WM), highlighting the significance of the MYD88, CXCR4, and TP53 mutations. He mentions the potential of targeted therapies dependent on the mutational status of individual patients. This interview took place at the 12th International Workshop on Waldenström's Macroglobulinemia (IWWM-12) in Prague, Czech Republic.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Смотрите видео The evolving role of genomics in the treatment of WM: MYD88, CXCR4, and TP53 онлайн без регистрации, длительностью часов минут секунд в хорошем качестве. Это видео добавил пользователь VJHemOnc – Video Journal of Hematology & HemOnc 24 Октябрь 2024, не забудьте поделиться им ссылкой с друзьями и знакомыми, на нашем сайте его посмотрели 114 раз и оно понравилось 1 людям.